Sanofi's four-price flu vaccine, Supertek, has been approved in the European Union to prevent influenza

The European Commission has approved Sanofi's four-price recombinant influenza vaccine, Supermtek, known as Flublok Quadrivalent, to prevent influenza in adults over the age of 18.
approval is based on data from two Phase III clinical trials, with a total of more than 10,000 participants.
trial results showed that Supemtek reduced the risk of influenza by a further 30 percent among adults 50 years and older compared to standard doses of the four-price flu vaccine based on eggs.
: Sanofi's official website Sanofi has developed Supertek using recombinant technology that matches exactly the key ingredients of the influenza strain recommended by the World Health Organization (WHO).
: Sanofi's official website says that between 290,000 and 650,000 flu-related deaths occur globally each year, and that there are about 10 million flu-related hospitalizations each year.
Sanofi expects Supertek to be launched in Europe during the 2022/2023 flu season.
in the context of the COVID-19 pandemic, the prevention of influenza remains a public health priority," said Thomas Triomphe, director of Sanofi Pasteur, a government agency.
" Sanofi has also used its recombinant technology to develop the COVID-19 vaccine, which will be used in combination with GlaxoSmithKline(GSK) ad technology.
Sanofi and GlaxoSmithKline announced in September that they would begin clinical testing of the vaccine candidate, and the first results of the study are expected to be released in early December.